Consequently,
Soon blood test predict relapses?:
Essential
- The start-up Altum Sequencing has developed a technology capable of detecting relapses of cancer, especially breast, up to 5.6 years before conventional methods. Nevertheless,
- This method. Furthermore, based on the analysis of tumor DNA circulating in the blood, is not very invasive, personalized and makes it possible to avoid unnecessary treatments. Moreover,
- Altum now aims to extend this technology to all types of solid tumors. In addition,

. Meanwhile,
What if a simple sample of blood was enough to anticipate the recurrence of cancer even before the appearance of symptoms? However, This is the promise of the Spanish start-up Altum Sequencing. supported by the Charles-III University in Madrid, which has just developed unprecedented technology for the post-treatment monitoring of solid tumors, including breast cancer. Details were soon blood test predict relapses? published in the journal Breast Cancer Research.

.
Anticipate the relapse, a crucial issue – Soon blood test predict relapses?
In women with hormone -dependent breast cancer, the most frequent, up to 40 % can relapse, sometimes several years after an apparent remission. But thanks to the analysis of circulating tumor DNA – DNA fragments from the tumor. present in the blood – Altum Sequencing technology makes it possible to detect these relapses up to 5.6 years before the classic methods. “Our goal is not to diagnose cancer. but to provide doctors with an effective tool to follow the evolution of the disease after treatment”explains Joaquín Martínez-López, president of Altum Sequencing, in a press release.

.
Technology is based on new generation DNA sequencing (NGS), capable of detecting “A tumor cell among a million healthy cells from a single blood sample”. The process begins with a biopsy of the initial tumor, followed by the identification of mutations specific soon blood test predict relapses? to each patient. Then, regular blood analyzes make it possible to identify the reappearance of these mutations.

.
“The advantage of our technology is that it is very little invasive, versatile and adapted to each type of tumor, underlines Marina Planas, CEO of the start-up. In addition, the cost is considerably reduced because it only targets relevant mutations for each patient. “

.
AI to further improve follow -up
Initially tested in blood cancers such as leukemia or myeloma, technology is already effective for other solid tumors, including pulmonary. Altum Sequencing is now targeting international authorization to disseminate its tool in hospitals. The company also incorporates generative artificial intelligence to improve the accuracy of monitoring and further personalize treatments. “Today, we detect a cell over a million. Tomorrow, it will be one in ten million”aims Marina Planas.
Consult our digital video book,
Only an account creation is required to access it.
Further reading: Advice to distinguish a benign from a more disturbing lesion – Will living by the sea become dangerous? – A blood test could predict the progression of the disease – A major study reveals that cannabis is a scourge for the heart and doubles the risk of death by cardiovascular disease – The national cancer register gives hope for better knowledge of the disease | Nurses.com | IDE profession.
